Literature DB >> 7860234

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885.

A Y Chang1, Z N Tu, G T Bryan, J M Kirkwood, M M Oken, D L Trump.   

Abstract

Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m2 by intravenous infusion over 30-60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7860234     DOI： 10.1007/bf00874447

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  7 in total

Review 1.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

Authors:  S A Rosenberg
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

Review 2.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; R S Witte; D L Trump
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

Review 4.  The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.

Authors:  R A Figlin; A S Abi-Aad; A Belldegrun; J B deKernion
Journal:  Semin Oncol       Date:  1991-10       Impact factor: 4.929

Review 5.  Hormonal therapy and chemotherapy of renal-cell carcinoma.

Authors:  D T Harris
Journal:  Semin Oncol       Date:  1983-12       Impact factor: 4.929

6.  Cytotoxic activity of echinomycin in a human tumor cloning system.

Authors:  B Lathan; D D Von Hoff
Journal:  Cancer Drug Deliv       Date:  1984

Review 7.  Echinomycin: the first bifunctional intercalating agent in clinical trials.

Authors:  B J Foster; K Clagett-Carr; D D Shoemaker; M Suffness; J Plowman; L A Trissel; C K Grieshaber; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850
  7 in total
  4 in total

1.  Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.

Authors:  Christopher M Bailey; Yan Liu; Gong Peng; Huixia Zhang; Miao He; Duxin Sun; Pan Zheng; Yang Liu; Yin Wang
Journal:  Nanomedicine       Date:  2020-07-30       Impact factor: 5.307

2.  Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.

Authors:  Yin Wang; Yan Liu; Fei Tang; Kelsie M Bernot; Reuven Schore; Guido Marcucci; Michael A Caligiuri; Pan Zheng; Yang Liu
Journal:  Blood       Date:  2014-07-03       Impact factor: 22.113

3.  Quinomycin A reduces cyst progression in polycystic kidney disease.

Authors:  Priyanka S Radadiya; Mackenzie M Thornton; Emily A Daniel; Jessica Y Idowu; Wei Wang; Brenda Magenheimer; Dharmalingam Subramaniam; Pamela V Tran; James P Calvet; Darren P Wallace; Madhulika Sharma
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.191

4.  Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes: in vitro anti-proliferative and anti-invasive activity in glioblastoma.

Authors:  Walhan Alshaer; Manar Zraikat; Amer Amer; Hamdi Nsairat; Zainab Lafi; Dana A Alqudah; Enas Al Qadi; Tasneem Alsheleh; Fadwa Odeh; Arwa Alkaraki; Malek Zihlif; Yasser Bustanji; Elias Fattal; Abdalla Awidi
Journal:  RSC Adv       Date:  2019-09-30       Impact factor: 4.036
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.